Archived article

Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.

Medical products firm had lagged the market but is now gaining momentum
Thursday 06 May 2021 Author: Tom Sieber

ConvaTec (CTEC) 223.8p

Gain to date: 9.3%

Original entry point: Buy at 204.6p, 23 December 2020

Shares in medical products firm Convatec (CTEC) are finally picking up, having been a laggard earlier this year thanks to a mix of sentiment shifting in favour of value stocks and concerns around pandemic-related disruption to the business.

Its latest update (29 Apr) seems to have won back the market’s attention. The company reported an 8.7% rise in revenue in the first quarter to $500 million, led by growth in its advanced wound care and infusion care business.

Advanced wound care revenue was up 8.8% on a reported basis, while ostomy care, its second largest business was up by 6.7%. Infusion care revenue increased by 13.9%, and continence and critical care revenue was up by 7.4%.

The company has maintained its full year outlook, citing ongoing macro uncertainties. For 2021, organic revenue growth is expected to be between 3% and 4.5%.

Numis analyst Paul Cudden says the numbers ‘provide further evidence that the turnaround has stuck’, adding that guidance looks ‘very conservative’.

SHARES SAYS: Convatec should benefit through the remainder of 2021 as elective surgeries delayed by Covid proceed. As a result, there’s a good chance of earnings upgrades. Buy. 

‹ Previous2021-05-06Next ›